

Accepted Manuscript

Benefits and limitations of randomized controlled trials: A Commentary on Deaton and Cartwright

Andrew Gelman



PII: S0277-9536(18)30201-6

DOI: [10.1016/j.socscimed.2018.04.034](https://doi.org/10.1016/j.socscimed.2018.04.034)

Reference: SSM 11714

To appear in: *Social Science & Medicine*

Please cite this article as: Gelman, A., Benefits and limitations of randomized controlled trials: A Commentary on Deaton and Cartwright, *Social Science & Medicine* (2018), doi: 10.1016/j.socscimed.2018.04.034.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Benefits and limitations of randomized controlled trials: A Commentary on Deaton and Cartwright

Andrew Gelman

gelman@stat.columbia.edu

Department of Statistics and Department of Political Science, Columbia University, New York

I agree with Deaton and Cartwright that randomized trials are often overrated. There is a strange form of reasoning we often see in science, which is the idea that a chain of reasoning is as strong as its strongest link. The social science and medical research literature is full of papers in which a randomized experiment is performed, a statistically significant comparison is found, and then story time begins, and continues, and continues—as if the rigor from the randomized experiment somehow suffuses through the entire analysis.

Here are some reasons why the results of a randomized trial cannot be taken as representing a general discovery:

1. **Measurement.** A causal effect on a surrogate endpoint does not necessarily map to an effect on the outcome of interest. Direct measurements also can be problematic if there is bias that is correlated with treatment assignment, as can occur in medical experiments without blinding or psychology experiments in which there is information leakage.
2. **Missing data.** Even a small proportion of dropout or nonresponse can bias the estimate of treatment effects, if missingness is correlated with outcome and treatment assignment.
3. **Extrapolation.** The participants in a controlled trial are typically not representative of the larger population of interest. This causes no problem if the treatment effect is constant but can lead to bias to the extent that treatment effects are nonlinear and have interactions. A related concern is realism: extrapolating from often-

Download English Version:

<https://daneshyari.com/en/article/7327414>

Download Persian Version:

<https://daneshyari.com/article/7327414>

[Daneshyari.com](https://daneshyari.com)